Device Trial Radar · NCT07569575
Magnesium-Titanium Hybrid Intramedullary Nail System For Long Bone Fractures
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
Nov 1, 2026
Primary completion
Mar 31, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- HuaMg Perfection Med Tech (Suzhou) Co., Ltd.Not on our public-company list
- Sponsor type
- Industry
- First posted
- May 6, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, multicenter, randomized, controlled, non-inferiority clinical trial designed to evaluate the safety and effectiveness of the magnesium-titanium hybrid intramedullary nail system compared with the marketed metal locked intramedullary nail in the treatment of long bone fractures of the extremities.
Conditions
- Tibial Fracture
- Femoral Fracture
- Humeral Fracture
Interventions
Magnesium-Titanium Hybrid Intramedullary Nail SystemDevice
The magnesium-titanium hybrid intramedullary nail system is inserted into the medullary canal through the proximal or distal end of the bone via standard intramedullary fixation surgical procedures, achieving fixation of the fracture site through intramedullary stabilization. This device provides load-sharing fixation for the fracture. The titanium alloy main body of the product delivers continuous, reliable mechanical support to ensure the overall stability of fracture fixation. The biodegradable magnesium components gradually degrade in vivo, releasing magnesium ions that participate in regulating the local bone repair microenvironment, thereby synergistically supporting the fracture healing process.
Commercially Locked Metallic Intramedullary NailDevice
Commercially available metallic intramedullary nails including the humeral intramedullary nail (NMPA Registration No. 20233130578) and locked intramedullary nail (NMPA Registration No. 20163131478) manufactured by Shandong Weigao Orthopaedic Device Co., Ltd. are selected as the control devices based on the following reasons: 1) Shandong Weigao Orthopaedic Device Co., Ltd. is a leading orthopaedic enterprise in China, and its products are widely used in clinical practice with well-established efficacy and safety profiles; 2) The indications of the control devices fully cover those of the investigational device.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Effective rate of the product at 180 days postoperativelyTime frame: 180±14 days postoperatively
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Beijing Jishuitan Hospital, Capital Medical University
Xicheng, Beijing Municipality, China
Henan Luoyang Orthopedic Hospital (Henan Orthopedic Hospital)
Luoyang, He'Nan, China
Hebei Medical University Third Hospital
Shijiazhuang, Hebei, China
2 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.